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Interventional Cardiology
Six-Month Versus 12-Month Dual Antiplatelet Therapy
After Implantation of Drug-Eluting Stents
The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After
Stenting (EXCELLENT) Randomized, Multicenter Study
Hyeon-Cheol Gwon, MD*; Joo-Yong Hahn, MD*; Kyung Woo Park, MD; Young Bin Song, MD;
In-Ho Chae, MD; Do-Sun Lim, MD; Kyoo-Rok Han, MD; Jin-Ho Choi, MD; Seung-Hyuk Choi, MD;
Hyun-Jae Kang, MD; Bon-Kwon Koo, MD; Taehoon Ahn, MD; Jung-Han Yoon, MD;
Myung-Ho Jeong, MD; Taek-Jong Hong, MD; Woo-Young Chung, MD; Young-Jin Choi, MD;
Seung-Ho Hur, MD; Hyuck-Moon Kwon, MD; Dong-Woon Jeon, MD; Byung-Ok Kim, MD;
Si-Hoon Park, MD; Nam-Ho Lee, MD; Hui-Kyung Jeon, MD; Yangsoo Jang, MD; Hyo-Soo Kim, MD
Background—The optimal duration of dual antiplatelet therapy (DAPT) after implantation of drug-eluting coronary stents
remains undetermined. We aimed to test whether 6-month DAPT would be noninferior to 12-month DAPT after
implantation of drug-eluting stents.
Methods and Results—We randomly assigned 1443 patients undergoing implantation of drug-eluting stents to receive 6- or
12-month DAPT (in a 1:1 ratio). The primary end point was a target vessel failure, defined as the composite of cardiac death,
myocardial infarction, or ischemia-driven target vessel revascularization at 12 months. Rates of target vessel failure at 12
months were 4.8% in the 6-month DAPT group and 4.3% in the 12-month DAPT group (the upper limit of 1-sided 95%
confidence interval, 2.4%; P0.001 for noninferiority with a predefined noninferiority margin of 4.0%). Although stent
thrombosis tended to occur more frequently in the 6-month DAPT group than in the 12-month group (0.9% versus 0.1%;
hazard ratio, 6.02; 95% confidence interval, 0.72–49.96; P0.10), the risk of death or myocardial infarction did not differ in
the 2 groups (2.4% versus 1.9%; hazard ratio, 1.21; 95% confidence interval, 0.60–2.47; P0.58). In the prespecified
subgroup analysis, target vessel failure occurred more frequently in the 6-month DAPT group than in the 12-month group
(hazard ratio, 3.16; 95% confidence interval, 1.42–7.03; P0.005) among diabetic patients.
Conclusions—Six-month DAPT did not increase the risk of target vessel failure at 12 months after implantation of
drug-eluting stents compared with 12-month DAPT. However, the noninferiority margin was wide, and the study was
underpowered for death or myocardial infarction. Our results need to be confirmed in larger trials.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00698607.
(Circulation. 2012;125:505-513.)
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Several randomized trials have demonstrated that drug-eluting coronary stents reduce angiographic restenosis
and target lesion revascularization compared with bare metal
stents.1–3 However, some long-term observational studies
have reported that the risk of death or myocardial infarction
was higher after drug-eluting stents than after bare metal
stents, which may be due to the different incidences of late or
very late stent thrombosis.4,5 Previous observational studies
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reported that premature discontinuation of thienopyridine
therapy was the major determinant of stent thrombosis after
implantation of drug-eluting stents6 and that the extended use
of clopidogrel in patients with drug-eluting stents may be
associated with a reduced risk of death or myocardial infarc-
tion.7 From the results of these reports, prolonged dual
antiplatelet therapy (DAPT; aspirin plus thienopyridine) of at
least 12 months is currently recommended after percutaneous
coronary intervention (PCI) with drug-eluting stents unless
patients are at high risk for bleeding.8
Editorial see p 471
Clinical Perspective on p 513
However, the optimal or minimal necessary duration of
DAPT remains undetermined. A randomized trial showed
that the use of DAPT for a period 12 months in patients
who had received drug-eluting stents was not significantly
more effective than aspirin monotherapy.9 Moreover, some
registry studies suggest that DAPT lasting 12 months after
PCI with drug-eluting stents does not increase major adverse
cardiac events and that there is no apparent clinical benefit
from DAPT for 6 months.10–12 To date, no randomized
trials have been performed to compare a shorter duration of
DAPT with 12-month DAPT. In the Efficacy of Xience/
Promus Versus Cypher to Reduce Late Loss After Stenting
(EXCELLENT) trial, we compared 6-month DAPT with
12-month DAPT in patients receiving drug-eluting stents.
Methods
Study Design and Patients
The EXCELLENT trial was a prospective, open-label, randomized
trial conducted at 19 sites in Korea. The authors designed the study,
and the institutional review board at each participating center
approved the trial protocol. The study design has previously been
described.13 Patients were eligible for inclusion in the study if they
had at least 1 lesion in a native coronary vessel with a reference
diameter of 2.25 to 4.25 mm, stenosis of50% by visual estimation,
and evidence of myocardial ischemia such as stable angina, unstable
angina, recent myocardial infarction, silent ischemia, a positive
functional study, or reversible changes on ECG consistent with
ischemia. Documentation of ischemia was not mandatory for lesions
with 75% stenosis. There were no limitations on the number of
lesions or the length of the lesions in efforts to reflect real-life
clinical practice. Exclusion criteria were myocardial infarction
within 72 hours; severely compromised ventricular dysfunction
(ejection fraction 25%) or cardiogenic shock; any stent implanta-
tion in the target vessel before enrollment; hemoglobin 10 g/dL or
platelet count 100 000 per 1 L; serum creatinine 265.2 mol/L
(3.0 mg/dL) or dependence on dialysis; serious hepatic disease;
major bleeding within 3 months or major surgery within 2 months;
allergy to antiplatelet drugs, heparin, stainless steel, contrast agents,
everolimus, or sirolimus; elective surgical procedure planned within
12 months; life expectancy 1 year; significant left main disease
defined as stenosis of 50%; chronic total occlusion; true bifurca-
tion lesions requiring a planned 2-stent strategy; or active participa-
tion in another clinical study. All patients provided written informed
consent.
Study Procedures and Follow-Up
Patients were randomly assigned in a 1:1 ratio to receive either
6-month DAPT (aspirin 100–200 mg/d plus clopidogrel 75 mg/d for
6 months and thereafter aspirin alone) or 12-month DAPT (aspirin
100–200 mg/d plus clopidogrel 75 mg/d for 12 months). Random-
ization was performed with a Web-based response system after
diagnostic angiography and before PCI. Randomization was strati-
fied by the site of enrollment, presence of diabetes mellitus, and
lesion length. In addition, patients were randomly assigned to receive
everolimus- or sirolimus-eluting stents. The results of the drug-
eluting stent arm of the trial are not reported here.
PCI was performed according to standard techniques. Before the
index procedure, all patients received at least 300 mg aspirin and a
300- to 600-mg loading dose of clopidogrel unless they had
previously received these antiplatelet medications. Unfractionated
heparin was administered throughout the procedure to maintain an
activated clotting time of 250 seconds. Administration of glyco-
protein IIb/IIIa inhibitors was at the discretion of the operator. After
the procedure, all patients were recommended to receive optimal
pharmacological therapy, including statins, -blockers, or angioten-
sin-converting enzyme inhibitors at the discretion of the responsible
clinicians. Any P2Y12 receptor antagonist other than clopidogrel
was not used. Additionally, each investigator was advised to empha-
size the importance of cardiovascular risk factor modification to
patients.
Clinical follow-up was performed at 1, 3, 6, 9, and 12 months after
the index PCI. At follow-up, patient data, including clinical status, all
interventions, outcome events, and adverse events, were recorded. In
particular, information on the use of aspirin or clopidogrel was
assessed at each follow-up.
Study End Points
The primary end point was target vessel failure defined as a
composite of cardiac death, myocardial infarction, or target vessel
revascularization during the 12-month period after randomization.
Secondary end points included the individual components of the
primary end point; death resulting from any cause; death or myo-
cardial infarction; stent thrombosis; major bleeding according to the
Thrombolysis in Myocardial Infarction criteria14; major adverse
cardiocerebral events, which were a composite of death, myocar-
dial infarction, stroke, or any revascularization; and a safety end
point, which was a composite of death, myocardial infarction,
stroke, stent thrombosis, or Thrombolysis in Myocardial Infarc-
tion major bleeding.
Clinical events were defined on the basis of the recommendations
of the Academic Research Consortium.15 All deaths were considered
cardiac unless a definite noncardiac cause could be established.
During the first 48 hours after PCI, myocardial infarction was
defined as an increase of cardiac enzyme (creatine kinase-MB
fraction or troponin T/troponin I) 3 times above the upper limit of
normal in stable patients.15 In patients with elevated baseline levels
of cardiac enzyme, myocardial infarction was defined as a subse-
quent increase of 2-fold from baseline values.16 After the first 48
hours, myocardial infarction was defined as the presence of clinical
signs of myocardial infarction combined with a creatine kinase-MB
fraction or troponin T/troponin I increase higher than the upper limit
of normal.15 Target lesion revascularization was defined as either a
repeat PCI of the lesion within 5 mm of the deployed stent or bypass
graft surgery of the target vessel. Target vessel revascularization was
defined as repeat revascularization of the treated vessel by PCI or
bypass graft surgery. Stent thrombosis was defined as definite or
probable stent thrombosis according to the Academic Research
Consortium classification.15 Stroke, as detected by the occurrence of
a new neurological deficit, was confirmed by a neurologist and on
imaging. Device success was defined as the attainment at the target
site of a final residual diameter stenosis of 50% using only the
assigned study device. Lesion success was defined as the attainment
of a final residual diameter stenosis of50% using any percutaneous
method. Procedure success was defined as the attainment at the
target site of a final residual diameter stenosis of 50%, together
with the absence of any in-hospital major adverse cardiac events.
The independent clinical event adjudication committee (Table I in
the online-only Data Supplement), the members of which were
unaware of the study group assignments, assessed all of the clinical
end points.
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Statistical Analysis
The primary analysis was a noninferiority comparison of 6- and
12-month DAPT for the primary end point of target vessel failure
according to the intention-to-treat principle. Using data from large,
randomized clinical trials evaluating the efficacy of drug-eluting
stents, we estimated that the incidence of the primary end point with
12-month DAPT 1 year after the procedure would be 10%.17,18 The
noninferiority margin of 4.0 percentage points was chosen on
the basis of historical data,7 clinically acceptable relevance, and the
feasibility of study recruitment. We estimated that with a total of
1372 patients (686 per group), the power of the study would be 80%
to show noninferiority with a 1-sided type I error rate of 0.05.
Assuming that 5% of patients would be lost to follow-up, we
determined the final sample size to be 1440 patients (720 per group).
Continuous variables were presented as meanSD and compared
by use of the Student t test. Categorical variables were presented as
counts and percentages and compared by use of the 2 or Fisher
exact test as appropriate. Cumulative event rates were estimated with
the Kaplan-Meier method. If the upper limit of the 1-sided 95%
confidence interval (CI) of the difference were less than the
prespecified noninferiority margin, 6-month DAPT would be con-
sidered to be noninferior to 12-month DAPT. Survival curves were
compared by use of the log-rank tests. Hazard ratios with 95% CIs
were estimated by use of the Cox proportional-hazards method.
Landmark analysis19 was performed with a landmark of clopidogrel
discontinuation at 6 months among patients who were event free at
6 months. We also performed per-protocol analysis among patients
who adhered to the study protocol. The consistency of treatment
effects in prespecified subgroups was assessed by use of Cox
regression models with tests for interaction. P values and CIs were 2
tailed except those for noninferiority testing of the primary end point.
All analyses were performed with SAS version 9.1 (SAS Institute,
Inc, Cary, NC).
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Study Participants
Between June 2008 and July 2009, a total of 1443 patients
were enrolled. Of these patients, 722 were assigned to receive
6-month DAPT and 721 were assigned to receive 12-month
DAPT (Figure 1). Patients in the 2 groups were well balanced
with regard to most baseline demographic and clinical char-
acteristics (Table 1). However, patients with a history of
previous myocardial infarction were more common in the
6-month DAPT group compared with the 12-month group
(6.5% versus 3.7%; P0.02). Medications at discharge from
the index PCI were similar in the 6- and 12-month DAPT
groups. Angiographic and procedural data were also similar
in the 2 groups (Table 2). Everolimus-eluting stents were
used in three quarters of patients and sirolimus-eluting stents
were used in one quarter of patients as a result of 3:1
randomization of stents.
Study Outcomes
At 12 months, aspirin was continued in 99.9% of the 6-month
DAPT group and 99.3% of the 12-month DAPT group. The
median duration of DAPT was 190 days (interquartile range,
181–260 days) in the 6-month DAPT group and 375 days
(interquartile range, 364–395 days) in the 12-month DAPT
group. Adherence to the study protocol was 71.2% of the
6-month DAPT group and 93.2% of the 12-month DAPT
group at 12 months.
Follow-up regarding the primary end point was complete
in 99.1% of patients in the 6-month DAPT group and 98.8%
in the 12-month group. At 12 months, the primary end point
of target vessel failure was noted in 34 patients in the 6-month
DAPT group and 30 patients in the 12-month group. Cumu-
lative rates of target vessel failure at 1 year were 4.8% for the
6-month and 4.3% for the 12-month DAPT group. The
noninferiority of the 6-month DAPT to 12-month DAPT was
Figure 1. Trial profile. DAPT indicates dual antiplatelet therapy.
Table 1. Baseline Patient Characteristics
6-mo DAPT
(n722)
12-mo DAPT
(n721) P
Age, y 63.09.6 62.410.4 0.21
Male sex, n (%) 470 (65.1) 461 (63.9) 0.65
Body mass index, kg/m2 24.93.1 25.13.0 0.32
Diabetes mellitus, n (%) 272 (37.7) 278 (38.6) 0.73
Hypertension, n (%) 525 (72.7) 532 (73.8) 0.65
Dyslipidemia, n (%) 543 (75.2) 550 (76.3) 0.63
Current smoker, n (%) 198 (27.4) 186 (25.8) 0.49
Previous myocardial infarction, n (%) 47 (6.5) 27 (3.7) 0.02
Previous PCI, n (%) 67 (9.3) 62 (8.6) 0.65
Previous CABG, n (%) 11 (1.5) 7 (1.0) 0.34
Congestive heart failure, n (%) 4 (0.6) 5 (0.7) 0.75
Chronic renal failure, n (%) 6 (0.8) 9 (1.2) 0.44
Cerebrovascular disease, n (%) 47 (6.5) 48 (6.7) 0.91
Clinical presentation, n (%) 0.56
Silent ischemia/stable angina 353 (48.9) 346 (48.0)
Unstable angina/non–ST-segment–
elevation myocardial infarction
350 (48.5) 349 (48.4)
ST-elevation myocardial infarction 19 (2.6) 26 (3.6)
Ejection fraction, % 61.09.6 61.69.4 0.30
Discharge medications, n (%)
Aspirin 707 (99.4) 704 (99.0) 0.36
Clopidogrel 702 (98.7) 708 (99.6) 0.08
Statin 604 (85.0) 582 (81.9) 0.12
ACE inhibitor 224 (31.5) 243 (34.2) 0.28
Angiotensin II receptor antagonist 244 (34.3) 231 (32.5) 0.46
-blocker 427 (60.1) 445 (62.6) 0.33
DAPT indicates dual antiplatelet therapy; PCI, percutaneous coronary
intervention; CABG, coronary artery bypass grafting; and ACE, angiotensin-
converting enzyme. Data are meanSD when appropriate. Data are given for
the intention-to-treat population.
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statistically significant (absolute risk difference, 0.5 percent-
age points; upper limit of 1-sided 95% CI, 2.4%; P0.001 for
noninferiority; Table 3 and Figure 2A). Six-month landmark
analysis showed that the risk of target vessel failure at 12
months was not significantly higher in the 6-month DAPT
group than in the 12-month group (hazard ratio, 1.06; 95%
CI, 0.56–2.03; P0.85; Figure 2B). No significant differ-
ences were observed between the 2 groups in the secondary
end points (Table 3 and Figure 3). Although stent thrombosis
tended to occur more frequently in the 6-month DAPT group
than in the 12-month group (0.9% versus 0.1%; hazard
ratio, 6.02; 95% CI, 0.72– 49.96; P0.10), the risk of
death or myocardial infarction did not differ between the 2
groups (2.4% versus 1.9%; hazard ratio, 1.21; 95% CI,
0.60 –2.47; P0.58). Five of 6 stent thrombosis cases in
the 6-month DAPT group occurred before 6 months when
patients were taking both aspirin and clopidogrel. In the
remaining 1 patient who developed it after 6 months, stent
thrombosis occurred 89 days after discontinuation of
clopidogrel. In the 12-month DAPT group, there was only
1 case of stent thrombosis, which developed at 7 days after
the index procedure (Table 4).
The results from the per-protocol analysis were similar to
those from the intention-to-treat analysis. Target vessel fail-
ure occurred in 24 of 514 patients in the 6-month DAPT
group and 29 of 672 patients in the 12-month DAPT group.
Cumulative rates of target vessel failure at 1 year were 4.7%
for the 6-month DAPT group and 4.4% for the 12-month
DAPT group. The noninferiority of the 6-month DAPT to the
12-month DAPT was also statistically significant (absolute
risk difference, 0.3 percentage points; the upper limit of
1-sided 95% CI, 2.3%; P0.001 for noninferiority; Table II
and Figure I in the online-only Data Supplement). Although
stent thrombosis tended to occur more frequently in the
6-month DAPT group than in 12-month group (1.2% versus
0.2%; hazard ratio, 7.88; 95% CI, 0.95–65.44; P0.06), the
risk of death or myocardial infarction did not differ signifi-
cantly in the 2 groups (2.7% versus 2.1%; hazard ratio, 1.31;
95% CI, 0.63–2.75; P0.47; Table II and Figure II in the
online-only Data Supplement).
In prespecified subgroup analysis, the results of compari-
son between the 2 regimens were consistent across various
subgroups (Figure 4). However, there was significant inter-
action between diabetes mellitus and outcomes (interaction
P0.001). Target vessel failure occurred more frequently in
the 6-month DAPT group than in the 12-month group among
diabetic patients (hazard ratio, 3.16; 95% CI, 1.42–7.03;
P0.005), whereas it occurred less frequently in the 6-month
DAPT group than in the 12-month group among patients
without diabetes mellitus (hazard ratio, 0.44; 95% CI, 0.21–
0.94; P0.03). Results of detailed subgroup analysis accord-
ing to diabetic status are presented in Tables III and IV and
Figure IIIA and IIIB in the online-only Data Supplement.
Among diabetic patients, rates of myocardial infarction and
target vessel revascularization were significantly higher in the
6-month DAPT group than in the 12-month DAPT group
(4.5% versus 1.1%; hazard ratio, 4.14; 95% CI, 1.17–14.68;
P0.03; and 5.3% versus 1.9%; hazard ratio, 2.91; 95% CI,
1.05–8.08; P0.04, respectively). Stent thrombosis occurred
in 4 patients (1.5%) in the 6-month DAPT group compared
with none in the 12-month DAPT group among diabetic
patients. Although statistical significance was not achieved,
the risk of target vessel failure tended to be higher in the
6-month DAPT group than in the 12-month group among
patients receiving sirolimus-eluting stents, whereas such a
tendency was not observed in those receiving everolimus-
eluting stents (P for interaction0.18). We compared clinical
outcomes of 6-month and 12-month DAPT in detail accord-
ing to the type of stents (Tables V and VI and Figure IIIC and
IIID in the online-only Data Supplement). No significant
differences were observed in clinical outcomes between the
6- and 12-month DAPT groups among patients receiving
everolimus-eluting stents and patients receiving sirolimus-
eluting stents.
Discussion
In this prospective, randomized trial, 6-month DAPT was
noninferior to 12-month DAPT for the primary end point, the
rate of target vessel failure at 12 months. The 6-month
landmark analysis and per-protocol analysis showed consis-
tent results. However, target vessel failure occurred more
Table 2. Lesion and Procedural Characteristics
6-mo DAPT 12-mo DAPT P
Patients, n 722 721
Angiographic disease extent, n (%) 0.90
1-Vessel disease 347 (48.1) 346 (48.0)
2-Vessel disease 226 (31.3) 232 (32.2)
3-Vessel disease 149 (20.6) 143 (19.8)
Left anterior descending artery
treated, n (%)
452 (63.0) 447 (62.2) 0.73
Use of glycoprotein IIb/IIIa inhibitors,
n (%)
12 (1.7) 12 (1.7) 0.99
Use of intravascular ultrasound, n (%) 315 (43.6) 312 (43.3) 0.89
Treated lesions per patient, n 1.30.6 1.40.5 0.58
Stents per patient, n 1.61.0 1.60.9 0.39
Type of drug-eluting stents, n (%) 0.99
Everolimus 540 (74.8) 539 (74.8)
Sirolimus 182 (25.2) 182 (25.2)
Treated lesions, n 957 970
Left anterior descending artery, n (%) 482 (50.6) 474 (49.0) 0.51
ACC/AHA lesion class B2/C, n (%) 486 (52.8) 505 (53.8) 0.67
Long lesion (20 mm), n (%) 355 (40.3) 374 (41.2) 0.73
Total occlusion, n (%) 39 (4.2) 27 (2.9) 0.11
Thrombotic lesion, n (%) 74 (8.0) 73 (7.8) 0.84
Ulcerative lesion, n (%) 23 (24) 16 (1.6) 0.23
Bifurcation lesion, n (%) 98 (10.2) 111 (11.4) 0.42
Stents per lesion, n 1.20.5 1.20.5 0.41
Stent length per lesion, mm 27.813.0 28.313.7 0.31
Lesion success, n (%) 941 (99.7) 964 (99.8) 0.64
Device success, n (%) 941 (99.7) 963 (99.7) 0.98
Procedural success, n (%) 935 (99.0) 956 (99.0) 0.66
DAPT indicates dual antiplatelet therapy; ACC, American College of Cardi-
ology; and AHA, American Heart Association. Data are meanSD when
appropriate. Data are given for the intention-to-treat population.
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frequently with 6-month DAPT than with 12-month DAPT
among diabetic patients.
Prolonged DAPT of at least 12 months is currently recom-
mended after PCI with drug-eluting stents. Supporting this
guideline, several observational studies reported that the risk
of death or myocardial infarction increased after drug-eluting
stents compared with bare metal stents4,5 and that the ex-
tended use of clopidogrel in patients with drug-eluting stents
reduced the risk of death or myocardial infarction.7 However,
DAPT increases bleeding risk20,21 and costs compared with
aspirin alone. Endoscopic, dental, and surgical procedures are
often delayed because of prolonged DAPT, which may affect
the patient’s quality of life.22 Therefore, determining the
optimal or minimal necessary duration of DAPT is very
important.
Until now, the premature results of only 1 randomized trial
have been reported comparing the clinical outcomes of DAPT
versus aspirin alone beyond 12 months, and those results did
not support the use of DAPT for a period 12 months in
patients receiving drug-eluting stents.9 The study, however,
was not a dedicated randomized trial but a mixture of
different cohorts limited by the wide range of the duration of
antiplatelet therapy at the time of inclusion, and it was
underpowered mainly because of lower rate of primary end
point than expected. There has been no prospective random-
ized trial comparing 12 months and shorter durations of
DAPT after drug-eluting stent implantation. Several observa-
tional studies reported that discontinuation of thienopyridine
therapy beyond 6 months after implantation of drug-eluting
stents was not associated with an increased risk of stent
thrombosis.10,11 However, these studies were not randomized
trials and were limited by selection bias. In other words, there
have been no systematic studies to assess the optimal duration
of DAPT. Therefore, we performed a prospective, random-
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Figure 2. Kaplan-Meier curves for the pri-
mary end point of target vessel failure. P
values were calculated with the log-rank
test. A, A composite of cardiac death,
myocardial infarction, or target vessel re-
vascularization by intention-to-treat analy-
sis. B, Six-month landmark analysis
among patients who were event-free at 6
months. DAPT indicates dual antiplatelet
therapy.
Table 3. Clinical Outcomes
6-mo DAPT (n722),
n (%)
12-mo DAPT (n721),
n (%) HR* (95% CI) P
Target vessel failure† 34 (4.8) 30 (4.3) 1.14 (0.70–1.86) 0.60
Total death 4 (0.6) 7 (1.0) 0.57 (0.17–1.95) 0.37
Cardiac death 2 (0.3) 3 (0.4) 0.67 (0.11–3.99) 0.66
Myocardial infarction 13 (1.8) 7 (1.0) 1.86 (0.74–4.67) 0.19
Death/myocardial infarction 17 (2.4) 14 (1.9) 1.21 (0.60–2.47) 0.58
Target vessel myocardial infarction 12 (1.7) 6 (0.8) 2.00 (0.75–5.34) 0.16
Cerebrovascular accident 3 (0.4) 5 (0.7) 0.60 (0.14–2.51) 0.48
Target lesion revascularization 17 (2.4) 18 (2.6) 0.94 (0.49–1.83) 0.86
Target vessel revascularization 22 (3.1) 22 (3.2) 1.00 (0.56–1.81) 0.99
Any revascularization 43 (6.2) 43 (6.2) 1.00 (0.66–1.53) 0.99
Stent thrombosis 6 (0.9) 1 (0.1) 6.02 (0.72–49.96) 0.10
Any bleeding 4 (0.6) 10 (1.4) 0.40 (0.13–1.27) 0.12
TIMI major bleeding‡ 2 (0.3) 4 (0.6) 0.50 (0.09–2.73) 0.42
MACCE§ 56 (8.0) 60 (8.5) 0.94 (0.65–1.35) 0.72
Safety end point¶ 24 (3.3) 21 (3.0) 1.15 (0.64–2.06) 0.64
DAPT indicates dual antiplatelet therapy; HR, hazard ratio; CI, confidence interval; TIMI, Thrombolysis in Myocardial Infarction; and
MACCE, major cardiocerebral event. The percentages shown are Kaplan-Meier estimates from the intention-to-treat analysis.
*HRs are for the 6- versus 12-month DAPT group.
†Target vessel failure was a composite of cardiac death, myocardial infarction, or target vessel revascularization.
‡TIMI major bleeding refers to adjudicated events in accordance with previously used TIMI criteria.14
§MACCE was a composite of death, myocardial infarction, stroke, or any revascularization.
¶Safety end point was a composite of death, myocardial infarction, stroke, stent thrombosis, or TIMI major bleeding.
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ized study to compare 6- and 12-month DAPT in patients
receiving drug-eluting stents.
The main finding of our study was that the cumulative
incidences of target vessel failure did not differ significantly
between 6-month and 12-month DAPT. In addition, there
were no significant differences in the secondary end points
such as death/myocardial infarction, revascularization, or
major adverse cardiocerebral events. Our results confirm the
results of previous registry data that there were no apparent
clinical benefits from DAPT for 6 months.10–12 However,
stent thrombosis tended to occur more frequently in the
6-month DAPT group than in the 12-month group. The power
of our study was insufficient to reach conclusions regarding
the relationship between stent thrombosis and duration of
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Figure 3. Six-month landmark analysis for the key secondary end points. P values were calculated with the log-rank test. A, A com-
posite of death or myocardial infarction (MI). B, Stent thrombosis. C, Major adverse cardiocerebral events (MACCE; a composite of
death, MI, stroke, or any revascularization). D, Safety end point (a composite of death, MI, stroke, stent thrombosis, or Thrombolysis in
Myocardial Infarction major bleeding). DAPT indicates dual antiplatelet therapy.
Table 4. Detailed Information on Stent Thrombosis
Time to Stent
Thrombosis, d Classification Group Clinical Presentation Diabetic Status
Ejection
Fraction, %
Stent
Type Aspirin Clopidogrel Outcome
0 Definite 6-mo DAPT ST-segment–elevation
myocardial infarction
No 55 EES Continued Continued TLR
4 Definite 6-mo DAPT Stable angina Yes (OHA treated) 58 SES Continued Continued Myocardial
infarction
7 Probable 12-mo DAPT Unstable angina No 74 EES Continued Continued Death
15 Definite 6-mo DAPT Non–ST-segment–elevation
myocardial infarction
Yes (OHA treated) 62 EES Continued Continued Myocardial
infarction
17 Definite 6-mo DAPT Stable angina Yes (OHA treated) 70 SES Continued Continued Myocardial
infarction
173 Definite 6-mo DAPT Stable angina Yes (OHA treated) Not available EES Continued Continued TLR
273 Definite 6-mo DAPT Stable angina No 70 SES Continued Discontinued
at day 184
TLR
DAPT indicates dual antiplatelet therapy; EES, everolimus-eluting stent; TLR, target lesion revascularization; OHA, oral hypoglycemic agents; and SES,
sirolimus-eluting stent.
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DAPT. Prolonged DAPT for 6 months might be needed to
prevent late stent thrombosis because of delayed vascular
healing and inflammatory reaction after implantation of
drug-eluting stents.23,24 However, the majority of patients
were taking both aspirin and clopidogrel at the time of stent
thrombosis. Moreover, the timing of discontinuation of clopi-
dogrel and stent thrombosis in our study called into question
the temporal and causal relationship between discontinuation
and thrombosis.
The interesting result in this study is that the treatment
effect varied depending on the presence of diabetes mellitus.
Among diabetic patients, target vessel failure occurred more
frequently with 6-month DAPT than with 12-month DAPT.
Although these results might have occurred by chance,
several lines of evidences support our result. Diabetes melli-
tus is regarded as a proinflammatory and prothrombotic
condition,25,26 and patients with diabetes mellitus are more
frequently resistant to aspirin than those without diabetes
mellitus.27 In an observational study of diabetes mellitus,
longer use of clopidogrel was associated with a lower
incidence of death or myocardial infarction after implantation
of drug-eluting stents.28 The minimum necessary duration of
DAPT may be longer in diabetic than in nondiabetic patients.
Although a significant interaction between other conditions
and outcomes was not found, results from diabetic patients
can suggest that longer DAPT may be needed in high-risk
patients. These findings, however, should be interpreted with
caution, although they were derived from the prespecified
subgroup analysis.
There were several limitations to our study. First, the
primary end point was target vessel failure rather than hard
end points such as death or myocardial infarction. Consider-
ing the low rate of death or myocardial infarction in the
present study, tens of thousands of patients need to be
enrolled to compare death or myocardial infarction as the
primary end point. However, we do not think that including
revascularization could have biased our findings toward a
neutral effect on outcomes because it is unlikely that a shorter
duration of DAPT is superior to a longer one in terms of
revascularization. Revascularization is also one of the impor-
tant outcomes and might be included in the primary end point
to test noninferiority of 6-month DAPT more rigorously.
Second, the event rate was lower than expected, although
estimates of the event rate were based on data from previous
studies.17,18 As a result, the noninferiority margin of 4.0
percentage points was quite wide, considering that the rate of
target vessel failure was 4.3% with 12-month antiplatelet
therapy. The low event rate might be explained by several
possible factors. Our study was not an all-comer study, and
patients with high risk such as those with myocardial infarc-
tion within 72 hours, left main lesions, or severe left ventric-
ular dysfunction were excluded. Differences in interventional
practice such as frequent use of intravascular ultrasound may
play a role. Ethnic differences between our study and previ-
ous ones may be another potential contributor. Third, our
study was an open-label trial and was not placebo controlled.
This can affect study outcomes, including target vessel
revascularization, which was 1 component of the primary end
point, target vessel failure. Although all clinical end points
were assessed by members of independent clinical event
adjudication committee and statistical analyses were per-
formed by independent statisticians, operators were not
blinded to duration of clopidogrel. Fourth, apart from the
American College of Cardiology/American Heart Associa-
tion guideline for PCI,8 clopidogrel is recommended for at
least 12 months in patients receiving stent during PCI for
acute coronary syndromes.29 Patients who initially presented
with acute coronary syndromes and were allocated to the
6-month DAPT group might be at higher risk of events than
those whose initial presentation was stable angina. Finally, a
considerable proportion of patients in the 6-month DAPT
group received clopidogrel for 6 months. However,
6-month DAPT was also noninferior to 12-month DAPT in
the per-protocol analysis. Larger ongoing randomized trial
Figure 4. Subgroup analyses of the pri-
mary end point. DAPT indicates dual anti-
platelet therapy; HR, hazard ratio; CI,
confidence interval; ACS, acute coronary
syndrome; LV, left ventricular; EES,
everolimus-eluting stent; and SES,
sirolimus-eluting stent.
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such as the Safety and Efficacy of Six Months DAPT After
Drug-Eluting Stenting (ISAR-SAFE) trial (NCT00661206)
can provide more evidence regarding the safety of 6-month
DAPT. Until more confirmative evidence of the safety of
6-month DAPT is obtained, 6-month DAPT cannot be rec-
ommended in the general population undergoing PCI. Mean-
while, our results may be helpful for physicians to decide the
duration of DAPT case by case in real-world practice, eg, in
patients with increased bleeding risk or undergoing elective
surgery.
Conclusions
Our trial showed that the rate of target vessel failure was not
significantly different between the 6- and 12-month DAPT
groups after PCI with drug-eluting stents and that 6-month
DAPT was noninferior to 12-month DAPT in the risk of
target vessel failure. However, the noninferiority margin was
wide, and the study was underpowered for hard end points
such as death or myocardial infarction. The safety of a short
duration of DAPT in terms of stent thrombosis or in diabetic
patients should be studied in larger randomized trials.
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CLINICAL PERSPECTIVE
The optimal duration of dual antiplatelet therapy (DAPT) after implantation of drug-eluting coronary stents remains
undetermined. Although premature discontinuation of thienopyridine therapy was reported to be the major determinant of
stent thrombosis after implantation of drug-eluting stents, some studies suggest that there is no apparent clinical benefit
from DAPT for 6 months. In the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting
(EXCELLENT) trial, we compared 6-month DAPT with 12-month DAPT in patients receiving drug-eluting stents. Our
trial showed that the rate of target vessel failure was not significantly different between the 6- and 12-month DAPT groups
after percutaneous coronary intervention with drug-eluting stents (4.8% versus 4.3%) and that 6-month DAPT was
noninferior to 12-month DAPT in the risk of target vessel failure. However, stent thrombosis tended to occur more
frequently in the 6-month DAPT group than in the 12-month group (0.9% versus 0.1%). In subgroup analysis, target vessel
failure occurred more frequently in the 6-month DAPT group than in the 12-month group among diabetic patients (hazard
ratio, 3.16; 95% confidence interval, 1.42–7.03). Although 6-month DAPT cannot be recommended in the general
population on the basis of our trial, these data may be helpful for physicians to decide the duration of DAPT case by case
in real-world practice, eg, in patients with increased bleeding risk or undergoing elective surgery.
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Supplemental Table 2. Clinical outcomes by per-protocol analysis 
Data are n (%). The percentages shown are Kaplan–Meier estimates from the per-protocol analysis. DAPT 
indicates dual antiplatelet therapy. 
*Hazard rat ios (HR) are for the 6-month dual antiplatelet  therapy group as compared with the 12-month dual 
antiplatelet therapy group. 
†Target vessel failure was a composite of card iac death, myocardial infarction, or target vessel revascularizat ion.  
‡Thrombolysis in Myocardial Infarct ion (TIMI) major bleed ing refers to adjudicated events in accordance with 
previously used TIMI criteria.
 
§Major adverse cardiocerebral event (MACCE) was a composite of death, myocardial infarction, stroke, or any 
revascularizat ion. 
¶Safety endpoint was a composite of death, myocardial infarction, stroke, stent thrombosis, or TIMI major 
bleeding. 
  
 
6-month DAPT 
(n=514) 
12-month DAPT 
(n=672) 
HR (95%  CI)† P 
Target-vessel failure† 24 (4.7) 29 (4.4) 1.09 (0.63-1.87) 0.76 
Total death  4 (0.8) 7 (1.1) 0.75 (0.22-2.56) 0.64 
Card iac death  2 (0.4) 3 (0.5) 0.87 (0.15-5.22) 0.88 
Myocardial infarction  10 (2.0) 7 (1.1) 1.87 (0.71-4.92) 0.20 
Death / myocardial infarction 14 (2.7) 14 (2.1) 1.31 (0.63-2.75) 0.47 
Target vessel myocardial infarct ion 9 (1.8) 6 (0.9) 1.97 (0.70-5.52) 0.20 
Cerebrovascular accident  3 (0.6) 5 (0.8) 0.79 (0.19-3.28) 0.74 
Target-lesion revascularization 10 (2.0) 17 (2.6) 0.77 (0.35-1.68) 0.51 
Target-vessel revascularizat ion 14 (2.8) 21 (3.2) 0.88 (0.45-1.72) 0.70 
Any revascularization  29 (5.7) 42 (6.4) 0.90 (0.56-1.45) 0.67 
Stent thrombosis  6 (1.2) 1 (0.2) 7.88 (0.95-65.44) 0.06 
Any bleeding  4 (0.8) 9 (1.4) 0.58 (0.18-1.89) 0.37 
TIMI major bleeding‡  2 (0.4) 4 (0.6) 0.66 (0.12-3.60) 0.63 
MACCE§ 42 (8.2) 59 (8.8) 0.93 (0.63-1.38) 0.72 
Safety endpoint¶  21 (4.1) 21 (3.1) 1.32 (0.72-2.41) 0.37 
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Supplemental Table 3. Clinical outcomes among diabetic patients 
Data are n  (%). The percentages shown are Kaplan–Meier estimates from the intention-to-treat analysis. DAPT 
indicates dual antiplatelet therapy. 
*Hazard rat ios (HR) are for the 6-month dual antiplatelet  therapy group as compared with the 12-month dual 
antiplatelet therapy group. 
†Target vessel failure was a composite of card iac death, myocardial infarction, or target vessel revascularizat ion.  
‡Thrombolysis in Myocardial Infarct ion (TIMI) major bleed ing refers to adjudicated events in accordance with 
previously used TIMI criteria.
14 
§Major adverse cardiocerebral event (MACCE) was a composite of death, myocardial infarction, stroke, or any 
revascularizat ion. 
¶Safety endpoint was a composite of death, myocardial infarction, stroke, stent thrombosis, or TIMI major 
bleeding. 
  
 
6-month DAPT 
(n=272) 
12-month DAPT 
(n=278) 
HR (95%  CI)† P 
Target-vessel failure† 24 (9.1) 8 (3.0) 3.16 (1.42-7.03) 0.005 
Total death  2 (0.8) 3 (1.1) 0.68 (0.11-4.08) 0.68 
Card iac death  1 (0.4) 1 (0.4) 1.02 (0.06-16.32) 0.99 
Myocardial infarction  12 (4.5) 3 (1.1) 4.14 (1.17-14.68) 0.03 
Death / myocardial infarction 14 (5.3) 6 (2.2) 2.42 (0.93-6.31) 0.07 
Target vessel myocardial infarct ion 11 (4.1) 2 (0.7) 5.68 (1.26-25.63) 0.02 
Cerebrovascular accident  1 (0.4) 2 (0.7) 0.51 (0.05-5.64) 0.58 
Target-lesion revascularization 11 (4.2) 5 (1.9) 2.27 (0.79-6.54) 0.13 
Target-vessel revascularizat ion 14 (5.3) 5 (1.9) 2.91 (1.05-8.08) 0.04 
Any revascularization  23 (8.8) 14 (5.2) 1.71 (0.88-3.33) 0.11 
Stent thrombosis  4 (1.5) 0 (0) - 0.31 
Any bleeding  0 (0) 4 (1.5) - 0.31 
TIMI major bleeding‡  0 (0) 0 (0) - - 
MACCE§ 33 (12.5) 21 (7.8) 1.66 (0.96-2.86) 0.07 
Safety endpoint¶  16 (6.0) 8 (2.9) 2.08 (0.89-4.86) 0.09 
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Supplemental Table 4. Clinical outcomes among non-diabetic patients 
Data are n  (%). The percentages shown are Kaplan–Meier estimates from the intention-to-treat analysis. DAPT 
indicates dual antiplatelet therapy. 
*Hazard rat ios (HR) are for the 6-month dual antiplatelet  therapy group as compared with the 12-month dual 
antiplatelet therapy group. 
†Target vessel failure was a composite of card iac death, myocardial infarction, or target vessel revascularizat ion.  
‡Thrombolysis in Myocardial Infarct ion (TIMI) major bleed ing refers to adjudicated events in accordance with 
previously used TIMI criteria.
14 
§Major adverse cardiocerebral event (MACCE) was a composite of death, myocardial infarction, stroke, or any 
revascularizat ion. 
¶Safety endpoint was a composite of death, myocardial infarction, stroke, stent thrombosis, or TIMI major 
bleeding. 
  
 
6-month DAPT 
(n=450) 
12-month DAPT 
(n=443) 
HR (95%  CI)† P 
Target-vessel failure† 10 (2.3) 22 (5.1) 0.44 (0.21-0.94) 0.03 
Total death  2 (0.5) 4 (0.9) 0.49 (0.09-2.70) 0.42 
Card iac death  1 (0.2) 2 (0.5) 0.49 (0.05-5.45) 0.57 
Myocardial infarction  1 (0.2) 4 (0.9) 0.25 (0.03-2.21) 0.21 
Death / myocardial infarction 3 (0.7) 8 (1.8) 0.37 (0.10-1.39) 0.14 
Target vessel myocardial infarct ion 1 (0.2) 4 (0.9) 0.25 (0.03-2.21) 0.21 
Cerebrovascular accident  2 (0.5) 3 (0.7) 0.66 (0.11-3.93) 0.65 
Target-lesion revascularization 6 (1.4) 13 (3.0) 0.45 (0.17-1.19) 0.11 
Target-vessel revascularizat ion 8 (1.8) 17 (4.0) 0.46 (0.20-1.07) 0.07 
Any revascularization  20 (4.6) 29 (6.8) 0.68 (0.38-1.19) 0.18 
Stent thrombosis  2 (0.5) 1 (0.2) 2.00 (0.18-21.81) 0.58 
Any bleeding  4 (0.9) 6 (1.4) 0.66 (0.19-2.33) 0.52 
TIMI major bleeding‡  2 (0.5) 4 (0.9) 0.49 (0.09-2.69) 0.41 
MACCE§ 23 (5.2) 39 (9.0) 0.57 (0.34-0.96) 0.03 
Safety endpoint¶  8 (1.8) 13 (3.0) 0.61 (0.25-3.67) 0.27 
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Supplemental Table 5. Clinical outcomes among patients receiving everolimus-eluting 
stents 
Data are n  (%). The percentages shown are Kaplan–Meier estimates from the intention-to-treat analysis. DAPT 
indicates dual antiplatelet therapy. 
*Hazard rat ios (HR) are for the 6-month dual antiplatelet  therapy group as compared with the 12-month dual 
antiplatelet therapy group. 
†Target vessel failure was a composite of card iac death, myocardial infarction, or target vessel revascularizat ion.  
‡Thrombolysis in Myocardial Infarct ion (TIMI) major bleed ing refers to adjudicated events in accordance with 
previously used TIMI criteria.
14 
§Major adverse cardiocerebral event (MACCE) was a composite of death, myocardial infarction, stroke, or any 
revascularizat ion. 
¶Safety endpoint was a composite of death, myocardial infarction, stroke, stent thrombosis, or TIMI major 
bleeding. 
  
 
6-month DAPT 
(n=540) 
12-month DAPT 
(n=539) 
HR (95%  CI)† P 
Target-vessel failure† 25 (4.7) 26 (4.9) 0.96 (0.56-1.66) 0.89 
Total death  3 (0.6) 4 (0.8) 0.75 (0.17-3.34) 0.70 
Card iac death  1 (0.2) 2 (0.4) 0.50 (0.05-5.49) 0.57 
Myocardial infarction  9 (1.7) 6 (1.1) 1.50 (0.53-4.21) 0.44 
Death / myocardial infarction 12 (2.3) 10 (1.9) 1.20 (0.52-2.78) 0.67 
Target vessel myocardial infarct ion 8 (1.5) 5 (0.9) 1.60 (0.52-4.89) 0.41 
Cerebrovascular accident  0 (0) 4 (0.8) 0.02 (0.00-47.17) 0.31 
Target-lesion revascularization 11 (2.1) 18 (3.5) 0.60 (0.29-1.28) 0.19 
Target-vessel revascularizat ion 16 (3.0) 20 (3.8) 0.80 (0.41-1.54) 0.50 
Any revascularization  30 (5.7) 35 (6.7) 0.85 (0.52-1.39) 0.51 
Stent thrombosis  3 (0.6) 1 (0.2) 3.00 (0.31-28.84) 0.34 
Any bleeding  3 (0.6) 9 (1.7) 0.33 (0.09-1.22) 0.10 
TIMI major bleeding‡  2 (0.4) 3 (0.6) 0.66 (0.11-3.97) 0.65 
MACCE§ 39 (7.4) 47 (8.9) 0.82 (0.54-1.26) 0.37 
Safety endpoint¶  16 (3.0) 16 (3.0) 1.00 (0.50-2.00) 0.99 
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Supplemental Table 6. Clinical outcomes among patients receiving sirolimus-eluting 
stents 
Data are n  (%). The percentages shown are Kaplan–Meier estimates from the intention-to-treat analysis. DAPT 
indicates dual antiplatelet therapy. 
*Hazard rat ios (HR) are for the 6-month dual antiplatelet  therapy group as compared with the 12-month dual 
antiplatelet therapy group. 
†Target vessel failure was a composite of card iac death, myocardial infarction, or target vessel revascularizat ion.  
‡Thrombolysis in Myocardial Infarct ion (TIMI) major bleed ing refers to adjudicated events in accordance with 
previously used TIMI criteria.
14 
§Major adverse cardiocerebral event (MACCE) was a composite of death, myocardial infarction, stroke, or any 
revascularizat ion. 
¶Safety endpoint was a composite of death, myocardial infarction, stroke, stent thrombosis, or TIMI major 
bleeding.
 
6-month DAPT 
(n=182) 
12-month DAPT 
(n=182) 
HR (95%  CI)† P 
Target-vessel failure† 9 (5.1) 4 (2.3) 2.31 (0.71-7.51) 0.16 
Total death  1 (0.6) 3 (1.7) 0.34 (0.04-3.25) 0.35 
Card iac death  1 (0.6) 1 (0.6) 1.01 (0.06-16.13) 0.99 
Myocardial infarction  4 (2.3) 1 (0.6) 4.07 (0.45-36.37) 0.21 
Death / myocardial infarction 5 (2.8) 4 (2.2) 1.27 (0.34-4.74) 0.72 
Target vessel myocardial infarct ion 4 (2.3) 1 (0.6) 4.07 (0.45-36.37) 0.21 
Cerebrovascular accident  3 (1.7) 1 (0.6) 3.03 (0.32-29.09) 0.34 
Target-lesion revascularization 6 (3.5) 0 (0) - 0.21 
Target-vessel revascularizat ion 6 (3.5) 2 (1.2) 3.09 (0.62-15.31) 0.17 
Any revascularization  13 (7.6) 8 (4.6) 1.68 (0.70-4.06) 0.25 
Stent thrombosis  3 (1.7) 0 (0) - 0.38 
Any bleeding  1 (0.6) 1 (0.6) 1.02 (0.06-16.26) 0.99 
TIMI major bleeding‡  0 (0) 1 (0.6) - 0.61 
MACCE§ 17 (9.8) 13 (7.3) 1.35 (0.66-2.79) 0.41 
Safety endpoint¶  8 (4.5) 5 (2.8) 1.64 (0.54-5.00) 0.39 
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Supplemental Figure Legends 
 
Supplemental Figure 1. Kaplan-Meier curves for the primary end point of target-vessel 
failure by per-protocol analysis 
P values were calculated with the use of the log-rank test. 
(A) A composite of cardiac death, myocardial infarction, or target vessel revascularization. (B) 
Six-month landmark analysis among patients who were event- free at 6 months. 
 
Supplemental Figure 2. Six-month landmark analysis for the key secondary end points 
by per-protocol analysis 
P values were calculated with the use of the log-rank test.  
(A) A composite of death or myocardial infarction (MI). (B) Stent thrombosis. (C) Major 
adverse cardiocerebral event (MACCE: a composite of death, myocardial infarction, stroke, 
or any revascularization). (D) Safety end point (a composite of death, myocardial infarction, 
stroke, stent thrombosis, or TIMI major bleeding). 
 
Supplemental Figure 3. Six-month landmark analysis for death or myocardial 
infarction (MI) according to diabetic status or stent types 
P values were calculated with the use of the log-rank test.  
(A) A composite of death or MI in patients with diabetes. (B) A composite of death or MI in 
patients without diabetes. (C) A composite of death or MI in patients receiving everolimus-
eluting stents. (D) A composite of death or MI in patients receiving sirolimus-eluting stents. 
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